Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cefuroxime Sodium

FDA-approved product (injectable, injection), marketed as Cefuroxime And Dextrose In Duplex Container, Cefuroxime Sodium, Cefuroxime Sodium In Plastic Container and 4 more.

Registered studies
50+
Lab records
17
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cefuroxime Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Eye infection
  • Infection
  • Pneumonia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Second-generation cephalosporins; Antibiotics
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DC02; WHO ATC S01AA27

Repurposing investigation

Cefuroxime Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA94.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli77.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae20.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis46.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 6 of 6 lab records
  • E. coli: measured active in 2 of 2 lab records
  • K. pneumoniae: measured active in 1 of 9 lab records
Open Cefuroxime Sodium in ChEMBL Registered studies below
Show the 17 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cefuroxime Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Risk of Acute Liver Injury in Users of Antimicrobials

    NCT01434173 · start 2001-07

    Registered record
    Registry ID
    NCT01434173
    Conditions
    Drug-Induced Liver Injury
    Interventions
    Moxifloxacin (Avelox, BAY12-8039); Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2001-07
    Completion
    2009-03
    Enrolment
    1,299,056

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-Induced Liver Injury
    InterventionMoxifloxacin (Avelox, BAY12-8039); Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
    PhaseNot recorded
    Registry statusCompleted

  • Study of the Efficacy of Preoperative Cefuroxime Prophylaxis to Prevent Surgical Site Infection in Herniated Disk Surgery

    NCT00530400 · start 1994-04

    Registered record
    Registry ID
    NCT00530400
    Conditions
    Surgical Wound Infection
    Interventions
    cefuroxime; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    1994-04
    Completion
    2000-03
    Enrolment
    1,369

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSurgical Wound Infection
    Interventioncefuroxime; placebo
    PhasePhase 4
    Registry statusCompleted

  • A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Cefuroxime Axetil in the Treatment of Adults With Persistent Bronchitis Experiencing Rapid Onset of Severe Worsening of Symptoms Caused by Bacteria

    NCT00269932 · start 1993-08

    Registered record
    Registry ID
    NCT00269932
    Conditions
    Bronchitis, Chronic
    Interventions
    levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1993-08
    Completion
    1994-05
    Enrolment
    485

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchitis, Chronic
    Interventionlevofloxacin
    PhasePhase 3
    Registry statusCompleted

  • A Study of the Safety and Effectiveness of Levofloxacin Compared With Ceftriaxone Sodium or Cefuroxime Axetil in the Treatment of Adults With Pneumonia

    NCT00257049 · start 1984-01

    Registered record
    Registry ID
    NCT00257049
    Conditions
    Pneumonia
    Interventions
    levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    1984-01
    Completion
    1995-01
    Enrolment
    604

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    Interventionlevofloxacin
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Preventing Frequent Sinus Infections in HIV-Infected Patients

    NCT00000752

    Registered record
    Registry ID
    NCT00000752
    Conditions
    HIV Infections; Sinusitis
    Interventions
    Pseudoephedrine hydrochloride; Guaifenesin; Cefuroxime axetil; Beclomethasone dipropionate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    Not recorded
    Completion
    1993-02
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Sinusitis
    InterventionPseudoephedrine hydrochloride; Guaifenesin; Cefuroxime axetil; Beclomethasone dipropionate
    PhasePhase 2
    Registry statusWithdrawn